A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

TMC278 25 mg tablet will be administered once daily.

TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.

TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.

Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.

Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.